H⁺/K⁺-ATPase inhibitors: a patent review

Abstract

Introduction: H⁺/K⁺-ATPase is a P-type ATP-driven cation transporter which exchanges ions (protons, chloride ions, and potassium ions) across the cell membrane. Modulators of H⁺/K⁺-ATPase affect H⁺/K⁺ exchange.

Areas covered: This article describes various H⁺/K⁺-ATPase inhibitors of biological importance in clinical studies and drug development for gastric acid-related diseases and gastrointestinal disorders.

Expert opinion: H⁺/K⁺-ATPase modulators have attracted much interest for their clinical implication in gastric acid-related diseases. Future studies of gastric H⁺/K⁺-ATPase inhibitors may focus on the correlation of pharmacogenetics and pharmacogenomics with the gastric acid secretion and development of more effective H⁺/K⁺-ATPase inhibitors to increase their residence time such as tenatoprazole and novel chemical-mediated absorption chemicals. The K⁺-competitive acid pump antagonists (APAs) are invented and independent of an acidic environment with better inhibition of the pump rapidly control acid secretion with a larger extent. The most innovative and promising compounds of APAs is AZD-0865, which is a modification of SCH28080. H⁺/K⁺-ATPase inhibitors can be tried to treat other diseases, especially viral infection after numerous clinical trials, and respiratory disease.

Keywords::

• antiviral
• asthma
• H⁺/K⁺-ATPase
• K⁺-competitive acid pump antagonists
• nasal polyps
• proton pump inhibitors
• Widal's syndrome

Notes

This box summarizes key points contained in the article.